Prodotti competitors / Area Oncology
Oncology Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
On the 26th of May 2023, CHMP released its meeting highlights for the month of May. The main discussion points of the meeting are as follows:
Recommendations on extensions of therapeutic indication
Opdivo (nivolumab)
- Indication: Used to treat adults with melanoma, NSCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, urothelial cancer, malignant pleural mesothelioma etc.
- The committee recommended Opdivo for extension of indication, which now includes Opdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%.
Following a CHMP opinion the European Commission usually takes a legally binding authorisation after 67 days or 35 days with an accelerated assessment.
Notification Link: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023
Document Source: Opdivo
Grazie per il tuo feedback!